Coenzyme Q₁₀ and Cardiovascular Diseases

• Main Authors: Francisco M. Gutierrez-Mariscal (Author), Silvia de la Cruz-Ares (Author), Jose D. Torres-Peña (Author), Juan F. Alcalá-Diaz (Author), Elena M. Yubero-Serrano (Author), José López-Miranda (Author)
• Format: Book
• Published: MDPI AG, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/antiox10060906; 2076-3921
• Keywords: coenzyme Q₁₀; ubiquinone; ubiquinol; cardiovascular diseases; Therapeutics. Pharmacology; RM1-950
• Source: Antioxidants, Vol 10, Iss 6, p 906 (2021)

Coenzyme Q₁₀ (CoQ₁₀), which plays a key role in the electron transport chain by providing an adequate, efficient supply of energy, has another relevant function as an antioxidant, acting in mitochondria, other cell compartments, and plasma lipoproteins. CoQ₁₀ deficiency is present in chronic and age-related diseases. In particular, in cardiovascular diseases (CVDs), there is a reduced bioavailability of CoQ₁₀ since statins, one of the most common lipid-lowering drugs, inhibit the common pathway shared by CoQ₁₀ endogenous biosynthesis and cholesterol biosynthesis. Different clinical trials have analyzed the effect of CoQ₁₀ supplementation as a treatment to ameliorate these deficiencies in the context of CVDs. In this review, we focus on recent advances in CoQ₁₀ supplementation and the clinical implications in the reduction of cardiovascular risk factors (such as lipid and lipoprotein levels, blood pressure, or endothelial function) as well as in a therapeutic approach for the reduction of the clinical complications of CVD.